ANATOMIC STAGE IIIA BREAST CANCER AJCC V8
Clinical trials for ANATOMIC STAGE IIIA BREAST CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new ANATOMIC STAGE IIIA BREAST CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for ANATOMIC STAGE IIIA BREAST CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a pill replace chemo for some breast cancers? major trial launches
Disease control Recruiting nowThis study compares two treatments for people with high-stage, estrogen-positive, HER2-negative breast cancer that has a low genetic risk of returning. One group gets standard hormone therapy plus a targeted pill (ribociclib), while the other gets chemotherapy first, then the sam…
Matched conditions: ANATOMIC STAGE IIIA BREAST CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…
Matched conditions: ANATOMIC STAGE IIIA BREAST CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could breast cancer patients skip extra immunotherapy? major trial aims to find out
Disease control Recruiting nowThis phase 3 trial is for people with early-stage triple-negative breast cancer who had a complete response to chemotherapy plus the immunotherapy drug pembrolizumab before surgery. It compares continuing pembrolizumab for 27 weeks after surgery versus simply watching and waiting…
Matched conditions: ANATOMIC STAGE IIIA BREAST CANCER AJCC V8
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Can new drug combos outsmart PARP resistance in BRCA breast cancer?
Disease control Recruiting nowThis phase 2 trial tests whether adding cediranib or ceralasertib to olaparib can overcome resistance in BRCA-mutated advanced breast cancer. About 60 participants with HER2-negative, BRCA-positive tumors that have progressed on prior therapy will receive one of the two drug comb…
Matched conditions: ANATOMIC STAGE IIIA BREAST CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Custom-Made vaccine takes on aggressive breast cancer
Disease control Recruiting nowThis early-phase trial is testing a personalized vaccine made from a patient's own tumor, given alone or with immune-boosting drugs (pembrolizumab or ipilimumab), for triple negative breast cancer. The goal is to see if the vaccine is safe and can train the immune system to attac…
Matched conditions: ANATOMIC STAGE IIIA BREAST CANCER AJCC V8
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
Electric field device combined with drugs tested for advanced cancers
Disease control Recruiting nowThis early-phase trial tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or nab-paclitaxel and atezolizumab in 43 people with advanced solid tumors in the abdomen or chest. The goal is to find the safest dose and see if…
Matched conditions: ANATOMIC STAGE IIIA BREAST CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Could a shorter, less toxic treatment be just as effective for early breast cancer?
Disease control Recruiting nowThis study is for people with early-stage triple-negative breast cancer. It compares a shorter chemo-immunotherapy regimen without anthracyclines (a type of strong chemo) to the usual longer treatment. The goal is to see if the shorter approach works just as well while reducing s…
Matched conditions: ANATOMIC STAGE IIIA BREAST CANCER AJCC V8
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo shows promise in shrinking tough breast cancer before surgery
Disease control Recruiting nowThis study tests whether adding the drug darolutamide to standard chemotherapy and immunotherapy before surgery can shrink tumors more effectively in people with early-stage androgen receptor positive triple-negative breast cancer. About 51 participants will receive either standa…
Matched conditions: ANATOMIC STAGE IIIA BREAST CANCER AJCC V8
Phase: PHASE2 • Sponsor: Vandana Abramson • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Exercise may sharpen memory in breast cancer survivors
Symptom relief Recruiting nowThis study tests whether a community-based exercise program can improve memory, attention, and brain health in women who have had breast cancer. About 160 survivors, aged 50 and older, will either take part in aerobic exercise or health education sessions. The goal is to see if p…
Matched conditions: ANATOMIC STAGE IIIA BREAST CANCER AJCC V8
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Laser therapy offers hope for breast cancer survivors suffering from vaginal dryness
Symptom relief Recruiting nowThis study tests a laser treatment for vaginal dryness in breast cancer survivors. Many survivors experience this side effect from cancer treatments like chemotherapy or hormone therapy. The trial will compare the laser to no treatment in 250 women to see if it improves symptoms.
Matched conditions: ANATOMIC STAGE IIIA BREAST CANCER AJCC V8
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
CBD oil tested for breast cancer drug side effect
Symptom relief Recruiting nowThis study tests whether a high-CBD plant extract can reduce joint stiffness and pain in women with breast cancer who take aromatase inhibitors. These drugs lower estrogen to prevent cancer return but often cause painful joints, leading some women to stop treatment. The trial wil…
Matched conditions: ANATOMIC STAGE IIIA BREAST CANCER AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Can rogaine help breast cancer patients keep their hair?
Symptom relief Recruiting nowThis early trial tests whether minoxidil (Rogaine) — applied to the scalp or taken as a pill — can help with hair loss caused by hormone therapy in breast cancer patients. About 50 women with stage I-IV breast cancer who report hair thinning since starting endocrine therapy will …
Matched conditions: ANATOMIC STAGE IIIA BREAST CANCER AJCC V8
Phase: EARLY_PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Friends and fitness: key to life after cancer?
Knowledge-focused Recruiting nowThis study follows 250 young adult cancer survivors to see how their social relationships and physical activity change over time and how these factors affect their quality of life. Participants wear an activity tracker and complete surveys. The goal is to learn how to better supp…
Matched conditions: ANATOMIC STAGE IIIA BREAST CANCER AJCC V8
Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
New tool helps breast cancer patients decide on preventive breast removal
Knowledge-focused Recruiting nowThis study tests a decision-making tool for women newly diagnosed with early-stage breast cancer who are considering removing the healthy breast as a preventive measure. The tool aims to improve knowledge and reduce uncertainty about the choice. Only 15 participants are enrolled,…
Matched conditions: ANATOMIC STAGE IIIA BREAST CANCER AJCC V8
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC